Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dexamethasone + tretinoin is a combination of two active pharmaceutical ingredients—a synthetic glucocorticoid corticosteroid (dexamethasone) and a retinoid (tretinoin, also known as all-trans retinoic acid). This combination is used in both topical and systemic formulations for various indications. Topically, it may be compounded to treat dermatological conditions such as melasma, post-inflammatory hyperpigmentation, acne scars, age spots, and vitiligo. Dexamethasone acts primarily as an anti-inflammatory agent by binding to the glucocorticoid receptor and modulating gene expression to suppress inflammation. Tretinoin promotes cell turnover by activating nuclear retinoic acid receptors (RARs), leading to increased epidermal cell proliferation and differentiation. Systemically or orally, the combination has been studied for immune modulation in diseases like primary immune thrombocytopenia—where dexamethasone provides immunosuppression while tretinoin exerts additional immunomodulatory effects that promote thrombopoiesis[3][8]. The synergistic effect of these agents has also been observed at the molecular level in gene regulation studies[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dexamethasone + tretinoin.